Xin Lang Cai Jing·2025-09-17 07:16Core Points - On September 17, Zhaoyan New Drug fell by 5.02%, trading at 40.08 CNY per share, with a transaction volume of 1.58 billion CNY and a turnover rate of 6.16%, resulting in a total market capitalization of 30.039 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs and preclinical research services, as well as the sale of laboratory animals and related products [1] Shareholder Analysis - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) increased its holdings by 2.2669 million shares in the second quarter, holding a total of 14.6531 million shares, which accounts for 1.96% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 31.0646 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a latest scale of 26.147 billion CNY, and has achieved a year-to-date return of 21.64% [2]